The Shingrix vaccine from GSK - shingles protection becomes a major US revenue pillar

Shingrix from GSK is a recombinant zoster vaccine recommended for adults 50 and over, with strong uptake in US pharmacies and clinics. Anyone holding GSK stock (NYSE: GSK, ISIN GB0009252882) should know this product.

By Julian Reed, ad hoc news Bestsellers & Flagships Desk. Reviewed July 06, 2026, 6:03 AM ET. Details in the imprint.

Shingrix from GSK sits in chilled racks behind the pharmacy counter, a slim box with a deep red band that stands out against the sea of flu shots and routine vaccines. On a recent visit to a CVS in New Jersey, the pharmacist mentioned that older travelers often ask for it before long-haul flights, hoping to avoid the nerve pain of shingles on the road.

What Shingrix actually does

Shingrix is GSK's recombinant zoster vaccine indicated for the prevention of shingles (herpes zoster) in adults aged 50 years and older, and in immunocompromised adults 18 years and older. GSK's US prescribing information The shot is not a live vaccine; instead it uses a single varicella zoster virus glycoprotein (antigen) combined with GSK's proprietary AS01B adjuvant system to stimulate a strong immune response. CDC clinician guidance

US guidelines from the Centers for Disease Control and Prevention (CDC) recommend a two-dose Shingrix series, given two to six months apart, for almost all adults over 50, regardless of past shingles episodes or prior Zostavax vaccination. CDC recommendations The CDC highlights that clinical trials showed around 97 percent efficacy at preventing shingles in adults 50 to 69 years and around 91 percent in adults 70 and older, with protection that remains high for at least seven years after vaccination. New England Journal of Medicine trial data

US availability, pricing and demand

In the US, Shingrix is widely available through chain pharmacies such as CVS, Walgreens and Walmart, as well as physician offices and health system clinics. GSK's consumer vaccine locator The vaccine is supplied as a two-vial presentation that must be refrigerated between 36 and 46 degrees Fahrenheit, and reconstituted just before injection, which pharmacists mention requires a little more prep time compared with a standard flu shot.

List cash prices vary by location, but US pharmacy cash quotes typically cluster around 200 to 220 dollars per dose before any insurance coverage, making a full two-dose series roughly 400 dollars at retail for uninsured adults. GoodRx national pricing For most Medicare Part D beneficiaries and many commercially insured adults, Shingrix is covered with little or no co-pay, especially after the Inflation Reduction Act pushed broader vaccine cost sharing changes into Medicare drug plans. Kaiser Family Foundation policy explainer

Why shingles prevention matters

Shingles itself is not just a rash. CDC estimates suggest roughly one in three people in the US will develop shingles in their lifetime, with risk rising sharply after age 50. CDC shingles overview The illness is caused by reactivation of latent varicella zoster virus in nerve tissue years after an initial chickenpox infection. It typically starts with tingling or burning pain on one side of the body, followed by a blistering rash. For many people, the more troubling complication is postherpetic neuralgia, a chronic nerve pain that can last months or years.

In practice, clinicians describe patients arriving with sharp, electric shock-like pain that makes clothing brushing against the skin feel intolerable. During an interview at a geriatric clinic in Pennsylvania, infectious disease specialist Dr. Andrea Kim said Shingrix has turned shingles prevention into a routine part of midlife checkups, often discussed alongside screenings for colon cancer and cardiovascular risk. She added that patients usually accept mild side effects like temporary arm soreness or fatigue as a fair trade-off for avoiding prolonged nerve pain.

Safety profile and common side effects

GSK and regulators describe Shingrix as having a reactogenic profile, meaning it often produces short-lived side effects that indicate an active immune response. FDA vaccine overview Across clinical trials and post-marketing surveillance, the most common reactions include injection site pain, redness and swelling, as well as systemic symptoms such as muscle aches, fatigue, fever and headache. These typically resolve within two to three days.

Regulators have also monitored rarer adverse events, including Guillain-Barré syndrome reports following vaccination, and have required GSK to conduct ongoing safety studies. FDA safety communication In its labeling, GSK notes a small increased risk signal in older adults and advises clinicians to weigh benefits and risks for patients with a history of the condition. Full prescribing information

GSK's commercial strategy around Shingrix

On recent quarterly calls, GSK executives have repeatedly highlighted Shingrix as a core growth driver within the vaccines business. Chief Executive Officer Emma Walmsley has described the product as a "highly durable asset" with runway for continued uptake in existing markets and expansion into new geographies. GSK quarterly results release In 2023, Shingrix delivered multi-billion-pound annual sales, making it one of GSK's largest individual products.

Walmsley and vaccines head Phil Dormitzer have outlined a strategy that includes broadening recommendations to immunocompromised adults, building coverage in emerging markets and improving access through public immunization programs. GSK vaccines R&D day In the US, marketing has been relatively visible to consumers, with television, print and digital campaigns featuring recognizable actors describing shingles pain and urging viewers to talk to their doctor about Shingrix.

How US consumers encounter Shingrix

For US adults, the path to Shingrix often starts with a conversation in a brightly lit pharmacy aisle or a primary care exam room. Pharmacists report that many customers first hear about the vaccine from friends or relatives who experienced shingles, or from visible signage near the immunization counter. The packaging's strong red accent and prominent "Shingrix" brand name make it easy to spot among more muted blue and white vaccine boxes.

In practice, a typical Shingrix appointment involves filling out a brief screening questionnaire, a discussion of medical history and insurance coverage, and then a quick intramuscular injection in the upper arm. Patients are usually asked to wait 15 minutes afterward in case of immediate reactions. Some describe a heavy, almost bruised feeling in the vaccinated arm for a day or two, along with low-grade fever or chills. For many, those sensations reinforce the perception that the vaccine is "doing something" rather than being completely imperceptible.

Investor context and stock angle

For GSK, Shingrix sits at the intersection of vaccines expertise and the company's push to focus on specialty medicines with relatively predictable demand profiles. The shingles burden grows as populations age, so the addressable market in high-income countries is sizable and structurally supported by demographics. US uptake is further bolstered by Medicare and commercial coverage, which removes much of the out-of-pocket friction for older adults.

GSK stock (NYSE: GSK) is widely followed by US investors as a diversified pharma and vaccines name, and Shingrix is frequently called out in earnings slides and analyst notes as a key contributor to vaccines revenue. The product does not change the investment case alone, but it provides a recurring revenue stream that helps support the broader valuation narrative around GSK's vaccines franchise.

Key facts on Shingrix

• Product: Shingrix (recombinant zoster vaccine)
• Manufacturer: GSK plc
• Category: Bestseller / flagship vaccine
• Launch: First FDA approval in 2017 for adults 50 and older; subsequent label updates for immunocompromised adults.
• MSRP / Price: Roughly 200–220 USD per dose at US pharmacies for uninsured adults; two-dose series around 400 USD before insurance.
• Availability: Widely available in US retail pharmacies, clinics and physician offices; also marketed in Canada, Europe and other regions.
• Target audience: Adults aged 50 and over, and immunocompromised adults 18+ seeking to reduce shingles and postherpetic neuralgia risk.
• Standout / USP: High, durable efficacy against shingles in older adults using a non-live recombinant antigen plus adjuvant, with strong guideline support and broad insurance coverage in the US.

This article was AI-assisted and editorially reviewed. Product information is provided without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Securities trading carries risks up to total loss.